Key result
Heart failure linked to ~4.5-fold higher mortality risk versus unaffected individuals.
Why the study?
Heart failure is a leading cause of global morbidity and mortality, but few studies have evaluated survival and prognostic factors considering recent therapeutic advances.
What is the survival rate and what are the prognostic factors associated with mortality in heart failure patients in the ELSA-Brasil cohort?
Cohort (n=15,105)
Yes
What is the survival rate and what are the prognostic factors associated with mortality in heart failure patients in the ELSA-Brasil cohort?
In the ELSA-Brasil cohort, participants with heart failure had an 80% survival rate over 12.3 years, with a significantly higher mortality risk than unaffected individuals, driven by male sex, older age, systolic dysfunction, hypertension, diabetes, and chronic kidney disease.
Underscores elevated long-term mortality risk in HF; extends prior observations to the ELSA-Brasil cohort without altering current management.
Background Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Few studies have evaluated the survival and prognostic factors of patients with this condition in light of the therapeutic advances of recent decades. Objectives To describe the survival, possible factors associated with mortality, and clinical characteristics of participants with HF in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Methods The cohort followed 15105 participants from 2008 to 2023. Sociodemographic variables, laboratory tests, electrocardiogram, two-dimensional echocardiogram, lifestyle habits, comorbidities, and medication use were evaluated. Survival probability was estimated using Kaplan-Meier curves and log-rank tests. Cox regression modeling was used to calculate the crude and adjusted Hazard Ratios (HR) with their respective 95% confidence intervals. The significance criterion was p<0.05. Results During the inclusion phase, 251 participants with an HF diagnosis were selected (2008-2010). Over approximately 12.3 years of follow-up, 48 (19%) died. The overall survival of participants with HF at 2, 6, 10, and 12.3 years of follow-up was 96%, 89%, 82%, and 80%, respectively. The mortality risk was 4.5 times higher (HR: 4.46; 95% CI: 3.3–5.9) compared to the unaffected group (p<0.01), and even after applying an adjusted model, the mortality risk remained twice as high (HR: 1.77; 95% CI: 1.3–2.4). Variables associated with a worse prognosis included male sex, advanced age, systolic dysfunction (LVEF<45%), hypertension, diabetes mellitus, and chronic kidney disease. Conclusion We found high mortality among participants with HF in the ELSA-Brasil cohort.
No takes yet. Share an insight, caveat, or question.
Lédo et al. (2025) conducted a cohort in Heart Failure (n=15,105). Heart Failure (Exposure) vs. No Heart Failure was evaluated on All-cause mortality (HR 4.46, 95% CI 3.33-5.97, p=<0.01). Heart failure was associated with a 4.5 times higher risk of mortality compared to unaffected individuals over a 12.3-year follow-up period (HR 4.46).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: